Use of oclacitinib in the treatment of vesicular cutaneous lupus erythematosus in a Border Collie breed dog – case report
DOI:
https://doi.org/10.33448/rsd-v11i15.36033Keywords:
Veterinary dermatology; Autoimmune disease; Vesicles; Janus kinase.Abstract
Vesicular cutaneous lupus erythematosus (VCLE) is a rare autoimmune inflammatory skin disease, a unique subacute variant of canine cutaneous lupus erythematosus. It affects adult Collie, Shetland Shepherd, Border Collie dogs and their crosses. In general, VCLE requires immunosuppressive treatments, which cause side effects and non-homogeneous therapeutic efficacy. A Border Collie dog, male, 3 years old, was diagnosed with VCLE. It showed a moderate response to the therapeutic combination of tetracycline-nicotinamide and later cyclosporine-ketoconazole. The objective of this study was to report the therapeutic success obtained with the use of oclacitinib, a Janus kinase inhibitor, in the control of VCLE lesions. The drug was administered at a dose of 0.6 mg/kg, orally, every 12 hours for 15 days and then every 24 hours for additional 20 days. Complete clinical resolution was observed in a few days, effectively and apparently without adverse effects. It is concluded that oclacitinib may be an advantageous alternative in the treatments of this variant of canine cutaneous lupus erythematosus. However, further studies on the use of Janus kinase inhibitors in the control of canine dermatological autoimmune diseases are needed.
References
Adolph, E. R., Scott D. W., Miller Jr W. H., & Hollis, N. E. (2014). Efficacy of tetracycline and niacinamide for the treatment of cutaneous lupus erythematosus in 17 dogs (1997-2011). The Japanese Journal of Veterinary Dermatology, 20(1), 9–15. http://doi 10.2736/jjvd.20.9
Aymeric, E., & Bensignor E. (2017). A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib. Veterinary Dermatology, 28(5), 512–e123. http://doi:10.1111/vde.12458.
Banovic, F., Robson, D., Linek, M., & Olivry T. (2017). Therapeutic effectiveness of calcineurin inhibitors in canine vesicular cutaneous lupus erythematosus. Veterinary Dermatology, 28(5), 493-e115. http://doi:10.1111/vde.12448.
Carrasco, I., Martinez, M., & Albinyana, G. (2021). Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus. Veterinary Dermatology, 32(3), 299–301. http://doi:10.1111/vde.12949
Collard, W., Hummel, B., Fielder, A., King, V. L., Boucher, J. F., Mullins, ... & M. R. Stegemann, M. R. (2014). The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. Journal of Veterinary Pharmacology and Therapeutics 37(3), 279–285. http://doi:10.1111/jvp.12087
Fetter, T., Smith, P., Guel, T., Braegelmann. C.; Bieber. T., & Wenzel, J. (2020). Selective Janus Kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Frontiers of Immunology., Sec. Autoimmune and Autoinflammatory Disorders, 11:344. http://doi.org/10.3389/fimmu.2020.0034
Gross, T. L., Ihrke, P. J., Walder E. J., & Affolter, K. V. (2009). Doenças de pele do cão e do gato, Diagnóstico clínico e histopatológico, 2ª. edição, Ed. Roca, p. 59-61.
High, E.J., Linder, K.E., Mamo, L.B., Levy, B. J., Herrmann, I., & Bizikova, P. (2020). Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two dogs. Veterinary Dermatology, 32(4), 330-e86. http://doi:10.1111/vde.12852
Hosseini, A., Gharibi, T., Marofi, F., Javadiano, M., Babaloo, Z., & Baradaran, B. (2019). Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. autoimmune diseases. Journal of Cellular Physiology, 235(9), 5903–5924. http://doi:10.1002/jcp.29593
Jackson, H. A., & Olivry T. (2001). Ulcerative dermatosis of the Shetland sheepdog and rough Collie dog may represent a novel vesicular variant of cutaneous lupus erythematosus. Veterinary Dermatology, 12(1),19-28. http://doi:10.1046/j.1365-3164.2001.00212.x
Jackson, H. A., Olivry T., Berget, F., Dunston, S. M., Bonnefont, C., & Chabanne, L. (2004). Immunopathology of vesicular cutaneous lupus erythematosus in the rough collie and Shetland sheepdog: a canine homologue of subacute cutaneous lupus erythematosus in human. Veterinary Dermatology, 15(4), 230-239. http://doi:10.1111/j.1365-3164.2004.00393.x
Jackson, H. A. (2004). Eleven cases of vesicular cutaneous lupus erythematosus in Shetland sheepdogs and rough collies: clinical management and prognosis. Veterinary Dermatology, 15(1), 37-41, http://doi:10.1111/j.1365-3164.2004.00355.x
Jackson, H. A. (2006). Vesicular Cutaneous Lupus. Small Animal Practice, 36(1), 251-255. http://doi:10.1016/j.cvsm.2005.09.005
Larsson, C. E. & Lucas, R. (2020). Tratado de Medicina Externa Dermatologia Veterinária, 2ª edição, Ed. Interbook Editorial, pp. 875-890.
Levy, B. J., Linder, K. E., & Olivry, T. (2019). The role of oclacitinib in the management of ischaemic dermatopathy in four dogs. Veterinary Dermatology, 30(3), 201-e63, http://doi:10.1111/vde.12743
Lucina, S. B., Farias, M. R., & Werner, J. (2014). Lúpus eritematoso cutâneo vesicular em um cão sem raça definida: relato de caso. Medvep Dermato - Revista de Educação Continuada em Dermatologia e Alergologia Veterinária, 3(8), 84-86.
Olivry, T. (2018). Auto-immune skin diseases in animals: time to reclassify and review after 40 years. BMC Veterinary Research, 14(1), 157, http://doi:10.1186/s12917-018-1477-1.
Olivry, T., Linder, K. E., & Banovic, F. (2018). Cutaneous lupus erythematosus in dogs: a comprehensive review. BMC Veterinary Research, 14(1), 132, http://doi:10.1186/s12917-018-1446-8
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica. Santa Maria/RS. Ed. UAB/NTE/UFSM, pp 65-74.
Shreberk-Hassidim, R., Ramot, Y., & Zlotogorski, A. (2017). Janus kinase inhibitors in dermatology: a systematic review. Journal of the American Academy of Dermatology, 76 (4), 745-753.e19. http://doi:10.1016/j.jaad.2016.12.004.
White, S. D., Rosychuk, R. A., Reinke, S. I., & Paradis, M. (1992). Use of tetracycline and niacinamide for treatment of autoimmune skin disease in 31 dogs. Journal of the American Veterinary Medical Association, 200 (10), 1497-500.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Anna Karina Lima; Felipe Rosa Cunha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
